Pharma R&D Today

Ideas and Insight supporting all stages of Drug Discovery & Development

Select category
Search this blog

The Change Imperative: Finding the right balance as times change

Posted on March 27th, 2017 by in Pharmacovigilance

I was delighted to chair a CPD Pharmacovigilance meeting last week in Berlin. I had been asked to share perspectives from the discussions within the Pharmaceutical Special Interest group at the Chartered Institute of Ergonomics and Human Factors. Continue reading “The Change Imperative: Finding the right balance as times change” »

Building a balanced search formula for pharmacovigilance and literature monitoring

Posted on March 21st, 2017 by in Pharmacovigilance

Adverse drug reactions are an important risk for patient safety and have significant impact on the costs of health systems. A rise in number of diseases has consequently led to a rise in number of drug consumption, which has also brought about an increase in the number of adverse drug events and drug toxicity cases. Continue reading “Building a balanced search formula for pharmacovigilance and literature monitoring” »

PV Audit by Quality: Friends or Foes?

Posted on March 9th, 2017 by in Pharmacovigilance

One of the major ways to measure the health of a Pharmacovigilance (PV) organization is to organize regular audits by experienced Quality Assurance (QA) auditors. During such audits, how open should PV be with the auditors Continue reading “PV Audit by Quality: Friends or Foes?” »

Debates on Pharmacovigilance – What’s new and trending

Posted on March 2nd, 2017 by in Pharmacovigilance

Fleming’s Pharmacovigilance & Risk Management Strategies Forum is always an excellently organized event, attended by industry leaders, policy makers and legislators. Continue reading “Debates on Pharmacovigilance – What’s new and trending” »

  1. 1
  2. 2
  3. 3
  4. 11